<SEC-DOCUMENT>0001683168-16-000085.txt : 20160913
<SEC-HEADER>0001683168-16-000085.hdr.sgml : 20160913
<ACCEPTANCE-DATETIME>20160913160510
ACCESSION NUMBER:		0001683168-16-000085
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160912
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20160913
DATE AS OF CHANGE:		20160913

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SIMULATIONS PLUS INC
		CENTRAL INDEX KEY:			0001023459
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMPUTER INTEGRATED SYSTEMS DESIGN [7373]
		IRS NUMBER:				954595609
		FISCAL YEAR END:			0831

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32046
		FILM NUMBER:		161882922

	BUSINESS ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		STREET 2:		*
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
		BUSINESS PHONE:		661-723-7723

	MAIL ADDRESS:	
		STREET 1:		42505 10TH STREET WEST
		CITY:			LANCASTER
		STATE:			CA
		ZIP:			93534-7059
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>simulations_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><B>UNITED STATES</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">SECURITIES AND EXCHANGE COMMISSION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">WASHINGTON, D.C. 20549</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">FORM 8-K</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">CURRENT REPORT</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">  September
12, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">(Date of the
earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Simulations Plus, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">(Exact name
of registrant as specified in its charter)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="width: 33%; text-align: center"><B>California</B></TD>
    <TD STYLE="width: 34%; text-align: center"><B>001-32046</B></TD>
    <TD STYLE="width: 33%; text-align: center"><B>95-4595609</B></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
    <TD STYLE="text-align: center"><FONT STYLE="font-weight: normal">(State
or other jurisdiction of incorporation)</FONT></TD>
    <TD STYLE="text-align: center"> (Commission File Number)</TD>
    <TD STYLE="text-align: center"> (I.R.S. Employer Identification No.)</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">42505 10<SUP>th</SUP> Street West, Lancaster,
California 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">(Address of
principal executive offices) (Zip Code)</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">661-723-7723</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">Registrant's
telephone number, including area code</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Soliciting material pursuant to Rule 14z-12 under Exchange Act (17 CFR 240.14a-12) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under Exchange Act (17 CFR 240.14d-2(b)) </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">[
&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under Exchange Act (17 CFR 240.13e-4(c))</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><FONT STYLE="font-weight: normal"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 8.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<FONT STYLE="font-size: 10pt">Other
Events</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On September 12, 2016, Simulations Plus, Inc.,
a California corporation (the &quot;Company&quot;), issued a press release announcing preliminary revenues for the fourth fiscal
quarter and fiscal year ended August 31, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The information contained in this Current Report
on Form 8-K shall not be deemed to be &quot;filed&quot; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the &quot;Exchange Act&quot;), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended (the &quot;Securities Act&quot;), or the Exchange Act,
except as shall be expressly set forth by specific reference in such a filing. The information set forth in this Current Report
on Form 8-K shall not be deemed an admission as to the materiality of any information in this report on Current Report on Form
8-K that is required to be disclosed solely to satisfy the requirements of Regulation FD.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>CAUTION REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">This Current Report on Form 8-K may contain
forward-looking statements that are made pursuant to the safe harbor provisions of Section 21E of the Exchange Act. The forward-looking
statements in this Current Report on Form 8-K are not historical facts, do not constitute guarantees of future performance and
are based on numerous assumptions which, while believed to be reasonable, may not prove to be accurate. Any forward-looking statements
in this Current Report on Form 8-K do not constitute guarantees of future performance and involve a number of factors that could
cause actual results to differ materially, including risks more fully described in our most recently filed Quarterly Report on
Form 10-Q and Annual Report on Form 10-K. The Company assumes no obligation to update any forward-looking information contained
in this Current Report or with respect to the announcements described herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Financial
Statements and Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Exhibits</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40pt; text-indent: 0in">99.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Press release issued on September 12, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Value: 2; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">SIGNATURES</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly
authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; text-indent: 0; margin-top: 0pt; margin-bottom: 6pt">&nbsp;</P>

<TABLE BORDER="0" CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">SIMULATIONS PLUS, INC.</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
    <TD STYLE="vertical-align: top; width: 50%">Dated: September   13, 2016</TD>
    <TD STYLE="width: 4%">By:</TD>
    <TD STYLE="vertical-align: top; width: 46%">/s/ John R. Kneisel</TD></TR>
<TR>
    <TD STYLE="vertical-align: top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="vertical-align: top; border-top: #000000 1px solid">John R. Kneisel<BR>Chief Financial Officer</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: left; margin-bottom: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1.75in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>simulations_8k-ex9901.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">Exhibit 99.1</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Further Information:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">42505 10<SUP>th</SUP> Street West</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Lancaster, CA 93534-7059</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%"><FONT STYLE="font-size: 10pt"><B>CONTACT</B>:</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Simulations Plus Investor Relations</U></FONT></TD>
    <TD STYLE="text-decoration: underline"><FONT STYLE="font-size: 10pt"><U>Hayden IR</U></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ms. Renee Bouche</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Mr. Cameron Donahue</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">661-723-7723</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">651-653-1854</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">renee@simulations-plus.com</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">cameron@haydenir.com</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">For Immediate Release:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">September 12, 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Simulations
Plus Reports Preliminary Revenues for </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Fourth Quarter
and Fiscal Year 2016</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><I>Company Reports Record Fourth-Quarter
and Full-Year Revenues</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>LANCASTER, CA, September 12, 2016<FONT STYLE="color: red">
</FONT>&ndash; </B>Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of consulting services and software for pharmaceutical
discovery and development, today released preliminary revenues for its fiscal fourth quarter (4QFY16) and full fiscal year 2016
(FY2016) ended August 31, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Mr. John R. Kneisel, chief financial officer
of Simulations Plus, stated: &ldquo;We have completed our second year of operations following our September 2014 acquisition of
Cognigen Corporation; an acquisition which delivered the expected benefits such as expanded addressable market, synergies across
our software and consulting business, increased scale, and greater profitability. In accordance with our policy to release timely
financial information to our shareholders, we are releasing preliminary consolidated annual and fourth quarter revenues. Net income
will not be released until completion of our annual audit and review of our Annual Report on Form 10-K. We expect to file our 10-K
with the U.S. Securities and Exchange Commission on or before the November 14, 2016 deadline.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Preliminary results for the fiscal year:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Consolidated software and software-related services increased 10.7% to a record $13.85 million
for FY2016 compared to $12.5 million in FY2015</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Consolidated consulting revenues increased 4.1%, or $238,000, to $6.04 million compared to $5.80
million in FY2015</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Total preliminary consolidated revenues for FY2016 increased 8.6%, or $1.57 million, to a record
$19.89 million, compared to $18.31 million for FY2015</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For FY2016, approximately 69.5% of revenues came from software licenses and software-related services
and approximately 30.5% of revenues came from consulting studies and collaborations</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Cash remains strong. As of August 31, 2016, cash was $8.0 million after distributing approximately
$861,000 in dividends to shareholders on August 18, 2016 (for a total of $3.41 million in dividends distributed during FY2016),
along with payments to TSRL and the final payment of $720,000 for the Cognigen acquisition made in July. Cash as of today is $8.5
million.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Preliminary results for the quarter:</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Consolidated software and software-related services increased 19.1% to a record $2.60 million for
4QFY16 compared to $2.18 million in 4QFY15</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Consolidated 4QFY16 consulting revenues decreased 16.6%, or $225,000, to $1.28 million from $1.53
million in 4QFY15, impacted by several customers&rsquo; failed clinical trials and delayed trials that we noted last quarter</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Total preliminary revenues for 4QFY16 increased 4.4% to $3.87 million, a new fourth quarter record,
compared to $3.71 million reported for 4QFY15</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">For the quarter, approximately 66.3% of revenues came from software and software-related services,
and approximately 33.7% of revenues came from consulting studies and collaborations</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">During 4QFY16, the company added 21 new software customers and a total of 76 for FY2016</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Annual recurring customer renewal rate was 88% (total accounts) and 95% based on revenue.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">John DiBella, vice president for marketing
and sales of Simulations Plus, said: &ldquo;As anticipated, FY2016 finished on a solid note, with a substantial percentage of software
revenue growth coming from new clients, including several licenses from non-pharmaceutical markets subscribing to our tools. The
pipeline for PBPK and pharmacometric modeling projects is strong and continues to improve as we head into FY2017, helping to offset
a modest decrease in consulting revenue in the fourth quarter of fiscal year 2016. We have a busy fall season ahead of us, as we
are attending numerous conferences to promote several new product releases, including PKPlus&trade;, and hosting trainings and
workshops around the globe to continue to educate industry and regulatory scientists on mechanistic modeling &amp; simulation.
We believe these efforts should help us maintain our longstanding revenue growth momentum.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Walt Woltosz, chairman and chief executive
officer of Simulations Plus, added: &ldquo;We&rsquo;re very pleased with a 19% increase in software and software-related services
revenues. Of course, we&rsquo;re not satisfied with the negative growth in consulting revenues for the fourth quarter, but we are
pleased that for the fiscal year, consulting revenues showed over four percent increase in spite of the negative impact of the
third and fourth quarter effects when some of our customers&rsquo; clinical trials failed and some were delayed. With our announcement
of the launch of PKPlus&trade; two weeks ago and continued growth in our other software revenues and in our consulting business,
we are expecting a strong new fiscal year.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>About Simulations Plus, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Simulations Plus, Inc., is a premier developer
of drug discovery and development software as well as a leading provider of both preclinical and clinical pharmacometric consulting
services for regulatory submissions. The company is a global leader focused on improving the ways scientists use knowledge and
data to predict the properties and outcomes of pharmaceutical and biotechnology agents. Our software is licensed to and used in
the conduct of drug research by major pharmaceutical and biotechnology companies and regulatory agencies worldwide. Our innovations
in integrating new and existing science in medicinal chemistry, computational chemistry, pharmaceutical science, biology, and physiology
into our software have made us the leading software provider for physiologically based pharmacokinetic modeling and simulation.
For more information, visit our website at www.simulations-plus.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Follow Us on Twitter</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B>Safe Harbor Statement Under the Private
Securities Litigation Reform Act of 1995</B> &ndash; With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and uncertainties. Words like &ldquo;believe,&rdquo;
&ldquo;expect&rdquo; and &ldquo;anticipate&rdquo; mean that these are our best estimates as of this writing, but that there can
be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ
significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to:
our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by
our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to
attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company,
and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports as filed with
the U.S. Securities and Exchange Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">###</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  8$!08%! 8&!08'!P8("A *"@D)
M"A0.#PP0%Q08&!<4%A8:'24?&ALC'!86("P@(R8G*2HI&1\M,"TH,"4H*2C_
MVP!# 0<'!PH("A,*"A,H&A8:*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H
M*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"C_P  1"  O 04# 2(  A$! Q$!_\0
M'    @(# 0$             !@< !0$#! @"_\0 .Q   0,# @4"! ('" ,
M     0(#!  %$082!Q,A,5$402)A<8$5D0@C,D*AL<$6,U)48G*2T21$X?_$
M !D! 0 # 0$                ! @,$!?_$ "H1  $$  4$ 00# 0
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BHL)V@^0,8S73%C,1&0S%8:8:'4(:0$I'V%$6VI4J41?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
